Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Jun 19, 2026

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood
07:35

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood

Published on: December 24, 2016

Fast generation of dendritic cells.

P Kvistborg1, M Boegh, A W Pedersen

  • 1Dandrit Biotech A/S, Symbion Science Park, Copenhagen, Denmark.

Cellular Immunology
|October 13, 2009
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

IO102-IO103 immune-modulatory cancer vaccine and pembrolizumab in melanoma.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Properties of CD8 T-cell-recognized neoantigens in different tumor types.

Immuno-oncology technology·2025
Same author

Factors associated with long-term antibody response after COVID-19 vaccination in patients treated with systemic treatment for solid tumors.

ESMO open·2023
Same author

One-year data on immunogenicity and breakthrough infections in patients with solid tumors vaccinated against COVID-19 during systemic cancer treatment.

ESMO open·2023
Same author

Comparison of monocyte-derived dendritic cells from colorectal cancer patients, non-small-cell-lung-cancer patients and healthy donors.

Vaccine·2009
Same author

Phenotypic and functional markers for 1alpha,25-dihydroxyvitamin D(3)-modified regulatory dendritic cells.

Clinical and experimental immunology·2009
Same journal

Retraction notice to "Myeloid-derived suppressor cells accumulate in the liver site after sepsis to induce immunosuppression" Cellular Immunology 279 (2012) 12-20.

Cellular immunology·2026
Same journal

The uptake, intracellular trafficking and recycling of FcRn-blocking therapeutics in human endothelial cells in vitro.

Cellular immunology·2026
Same journal

Exosome-mediated immune modulation in rheumatoid arthritis and its role in synovial inflammation and autoimmune amplification.

Cellular immunology·2026
Same journal

Persistent CD4<sup>+</sup> T cell hyporesponsiveness during recovery from prolonged symptomatic SARS-CoV-2 infection.

Cellular immunology·2026
Same journal

Deficit in blood MAIT cells, altered cytokines and T cell dynamics in patients with coronary artery disease.

Cellular immunology·2026
Same journal

The circ_0003692-miR-1197-TLR4 axis: A key regulator in rheumatoid arthritis proliferation and inflammation.

Cellular immunology·2026
See all related articles

Fast dendritic cell (DC) protocols significantly shorten vaccine production time. DC generated in 48 hours or 5 days are comparable to the standard 8-day protocol, but 48-hour DC are more susceptible to IL-10 induction.

Area of Science:

  • Immunology
  • Cell Biology
  • Vaccinology

Background:

  • Dendritic cells (DCs) are crucial antigen-presenting cells for initiating immune responses.
  • DCs are utilized as vaccine adjuvants in clinical research.
  • Standard DC protocols require 8 days for generation (SDDC).

Purpose of the Study:

  • To develop and evaluate accelerated dendritic cell (DC) generation protocols.
  • To compare the efficacy of fast DC protocols (48h and 5-day) against the standard 8-day protocol (SDDC).
  • To assess phenotypic and functional characteristics of DCs produced by different protocols.

Main Methods:

  • Comparative analysis of two fast DC protocols against the standard 8-day DC protocol (SDDC).
  • Flow cytometry (FACS) analysis to evaluate DC phenotype (CD14, CD80, CD83, CD86, CCR7, HLA class I/II).

More Related Videos

Generation of Bone Marrow Derived Murine Dendritic Cells for Use in 2-photon Imaging
13:13

Generation of Bone Marrow Derived Murine Dendritic Cells for Use in 2-photon Imaging

Published on: July 9, 2008

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
06:09

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes

Published on: June 22, 2016

Related Experiment Videos

Last Updated: Jun 19, 2026

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood
07:35

Generation of Human Monocyte-derived Dendritic Cells from Whole Blood

Published on: December 24, 2016

Generation of Bone Marrow Derived Murine Dendritic Cells for Use in 2-photon Imaging
13:13

Generation of Bone Marrow Derived Murine Dendritic Cells for Use in 2-photon Imaging

Published on: July 9, 2008

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes
06:09

Generation of Immature, Mature and Tolerogenic Dendritic Cells with Differing Metabolic Phenotypes

Published on: June 22, 2016

  • Assessment of DC yield, morphology, and functional capacity, including response to TLR ligands (R848, LPS).

    • Main Results:

    • Two fast DC protocols (48h and 5-day) met optimal phenotypic criteria (CD14(low), CD80(high), CD83(high), CD86(high), CCR7(high), HLA class I/II(high)).
    • Phenotypic and functional comparability was observed between fast-generated DCs and SDDC.
    • DCs generated in 48 hours showed increased susceptibility to IL-10 induction by TLR ligands compared to SDDC.

    Conclusions:

    • Fast DC protocols (48h and 5-day) offer a viable alternative to SDDC, reducing production time.
    • The enhanced susceptibility of 48h DCs to IL-10 warrants careful monitoring of regulatory T cells in future clinical trials.
    • Further investigation through small phase I trials is recommended to determine the clinical relevance of fast DC protocols in cancer immunotherapy.